Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dinglong Culture Co Ltd
SZSE:002502
|
CN |
|
Global International Credit Group Ltd
HKEX:1669
|
HK |
|
X
|
Xiamen Voke Mold & Plastic Engineering Co Ltd
SZSE:301196
|
CN |
|
Vakif Gayrimenkul Yatirim Ortakligi AS
IST:VKGYO.E
|
TR |
Prescient Therapeutics Ltd
Total Equity
Prescient Therapeutics Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Total Equity
AU$17m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$574.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Equity
AU$23.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Total Equity?
Total Equity
17m
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's Total Equity amounts to 17m AUD.
What is Prescient Therapeutics Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
12%
Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Prescient Therapeutics Ltd have been -12% over the past three years , -5% over the past five years , and 12% over the past ten years .
